Literature DB >> 15309556

Strategies to influence PVR development.

Bernd Kirchhof1.   

Abstract

Proliferative vitreo-retinopathy (PVR) is a complication of rhegmatogenous retinal detachment or severe ocular trauma (intraocular foreign body, penetration, perforation, contusion, rupture). The risk of PVR varies from 10 to 40% depending on the original disease. Strategies to influence the risk of PVR include surgical techniques, pharmacological adjuncts, and preventive measurements. Surgical influences on the risk of PVR comprise: surgical skills (buckling, atraumatic procedure), primary vitrectomy, early vitrectomy, retinectomy, choice of vitreous tamponade agent. The influence of most such parameters is not confirmed by prospective randomized studies. Pharmaceutical adjuncts include daunomycin, 5-fluoruracil plus heparin and others. The influence of most such parameters has been studied by prospective randomized studies. The effect is statistically significant, its clinical relevance is subject of current discussion. Prevention of PVR, via prevention of injury, was successful in the past as shown by the reduction of wind screen injuries after the seatbelt legislation was installed, and reduction of work related injuries from protective eyewear. As for the treatment of existent PVR despite some progress in the past, there should be better ways of treatment ahead of us.

Entities:  

Mesh:

Year:  2004        PMID: 15309556     DOI: 10.1007/s00417-004-0978-8

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  48 in total

1.  Primary vitrectomy as a preventive surgical procedure in the treatment of severely injured eyes.

Authors:  J Faulborn; A Atkinson; D Olivier
Journal:  Br J Ophthalmol       Date:  1977-03       Impact factor: 4.638

2.  Early vitrectomy in the management of the severely traumatized eye.

Authors:  D J Coleman
Journal:  Am J Ophthalmol       Date:  1982-05       Impact factor: 5.258

3.  Risk factors for proliferative vitreoretinopathy after primary vitrectomy: a prospective study.

Authors:  C H Kon; R H Asaria; N L Occleston; P T Khaw; G W Aylward
Journal:  Br J Ophthalmol       Date:  2000-05       Impact factor: 4.638

4.  Biodegradable microspheres for vitreoretinal drug delivery.

Authors:  R Herrero-Vanrell; M F Refojo
Journal:  Adv Drug Deliv Rev       Date:  2001-10-31       Impact factor: 15.470

Review 5.  Proliferative vitreoretinopathy--is it anything more than wound healing at the wrong place?

Authors:  M Weller; P Wiedemann; K Heimann
Journal:  Int Ophthalmol       Date:  1990-03       Impact factor: 2.031

6.  Vitrectomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy: results of additional and long-term follow-up. Silicone Study report 11.

Authors:  G W Abrams; S P Azen; B W McCuen; H W Flynn; M Y Lai; S J Ryan
Journal:  Arch Ophthalmol       Date:  1997-03

7.  Does the presence of heparin and dexamethasone in the vitrectomy infusate reduce reproliferation in proliferative vitreoretinopathy?

Authors:  R G Williams; S Chang; M R Comaratta; G Simoni
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-08       Impact factor: 3.117

8.  Efficacy of daunorubicin encapsulated in liposome for the treatment of proliferative vitreoretinopathy.

Authors:  Kohtaro Shinohara; Minoru Tanaka; Toshiro Sakuma; Yasuhiko Kobayashi
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2003 Jul-Aug

9.  Retinectomy for treatment of intractable glaucoma: long term results.

Authors:  A M Joussen; P Walter; C P Jonescu-Cuypers; K Koizumi; V Poulaki; K U Bartz-Schmidt; G K Krieglstein; B Kirchhof
Journal:  Br J Ophthalmol       Date:  2003-09       Impact factor: 4.638

10.  [Proliferative vitreoretinopathy: relation to the extent of retinal detachment, size of retinal tears and coagulation surface].

Authors:  F Koerner; E Merz; A Wagner; B Gloor
Journal:  Klin Monbl Augenheilkd       Date:  1988-05       Impact factor: 0.700

View more
  24 in total

1.  Anti-EMP2 diabody blocks epithelial membrane protein 2 (EMP2) and FAK mediated collagen gel contraction in ARPE-19 cells.

Authors:  Shawn A Morales; David G Telander; Sergey Mareninov; Agnes Nagy; Madhuri Wadehra; Jonathan Braun; Lynn K Gordon
Journal:  Exp Eye Res       Date:  2012-06-19       Impact factor: 3.467

2.  Systemic corticosteroids reduce the risk of cellophane membranes after retinal detachment surgery: a prospective randomized placebo-controlled double-blind clinical trial.

Authors:  Fritz Koerner; Ursula Koerner-Stiefbold; Justus G Garweg
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-01-21       Impact factor: 3.117

3.  Tailored vitrectomy and laser photocoagulation without scleral buckling for all primary rhegmatogenous retinal detachments.

Authors:  K Johansson; M Malmsjö; F Ghosh
Journal:  Br J Ophthalmol       Date:  2006-07-12       Impact factor: 4.638

4.  PVR as a complication of rhegmatogeneous retinal detachment: a solved problem?

Authors:  S Joeres; B Kirchhof; A M Joussen
Journal:  Br J Ophthalmol       Date:  2006-06       Impact factor: 4.638

5.  Functional consequences of interactions between FAK and epithelial membrane protein 2 (EMP2).

Authors:  Shawn A Morales; Sergey Mareninov; Paige Coulam; Madhuri Wadehra; Lee Goodglick; Jonathan Braun; Lynn K Gordon
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-06-03       Impact factor: 4.799

6.  Deferred laser photocoagulation of relaxing retinotomies under silicone oil tamponade to reduce recurrent macular detachment in severe proliferative vitreoretinopathy.

Authors:  Marc Veckeneer; Kristel Maaijwee; David G Charteris; Jan C van Meurs
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-03-18       Impact factor: 3.117

Review 7.  Periostin in vitreoretinal diseases.

Authors:  Shigeo Yoshida; Takahito Nakama; Keijiro Ishikawa; Shintaro Nakao; Koh-Hei Sonoda; Tatsuro Ishibashi
Journal:  Cell Mol Life Sci       Date:  2017-09-14       Impact factor: 9.261

8.  Evaluation of 5-fluorouracil released from a foldable capsular vitreous body in vitro and in vivo.

Authors:  Haihua Zheng; Zhimin Wang; Peijuan Wang; Yaqin Liu; Zhaoxin Jiang; Qianying Gao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-11-27       Impact factor: 3.117

9.  Interaction of monocarboxylate transporter 4 with beta1-integrin and its role in cell migration.

Authors:  Shannon M Gallagher; John J Castorino; Nancy J Philp
Journal:  Am J Physiol Cell Physiol       Date:  2008-12-10       Impact factor: 4.249

10.  [Possible role of alkylphosphocholines in retinal reattachment surgery].

Authors:  K H Eibl; G P Lewis; K Betts; K A Linberg; A Gandorfer; S K Fisher; A Kampik
Journal:  Ophthalmologe       Date:  2007-11       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.